News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
141,943 Results
Type
Article (7829)
Company Profile (42)
Press Release (134072)
Section
Business (43454)
Career Advice (232)
Deals (5198)
Drug Delivery (11)
Drug Development (21188)
Employer Resources (35)
FDA (2569)
Job Trends (3612)
News (71908)
Policy (5192)
Tag
Academia (902)
Alliances (11945)
Alzheimer's disease (491)
Approvals (2555)
Artificial intelligence (36)
Bankruptcy (30)
Best Places to Work (3165)
Biotechnology (28)
Breast cancer (42)
Cancer (309)
Cardiovascular disease (35)
Career advice (217)
Cell therapy (62)
Clinical research (16092)
Collaboration (110)
COVID-19 (685)
C-suite (40)
Cystic fibrosis (28)
Data (392)
Diabetes (31)
Diagnostics (1499)
Earnings (10771)
Employer resources (33)
Events (21930)
Executive appointments (97)
FDA (2679)
Funding (105)
Gene editing (24)
Gene therapy (45)
GLP-1 (145)
Government (899)
Healthcare (3849)
Infectious disease (705)
Inflammatory bowel disease (38)
Interviews (31)
IPO (2026)
Job creations (621)
Job search strategy (199)
Layoffs (79)
Legal (870)
Lung cancer (43)
Manufacturing (32)
Medical device (1769)
Medtech (1771)
Mergers & acquisitions (3218)
Metabolic disorders (93)
Neuroscience (561)
NextGen Class of 2024 (1273)
Non-profit (1390)
Northern California (371)
Obesity (52)
Opinion (40)
People (17730)
Phase I (4797)
Phase II (6807)
Phase III (5618)
Pipeline (126)
Postmarket research (663)
Preclinical (3128)
Press Release (33)
Radiopharmaceuticals (45)
Rare diseases (59)
Real estate (1210)
Regulatory (3729)
Research institute (1020)
Series A (25)
Southern California (289)
Startups (1175)
United States (3225)
Vaccines (110)
Weight loss (29)
Date
Today (53)
Last 7 days (252)
Last 30 days (946)
Last 365 days (8945)
2024 (8155)
2023 (10133)
2022 (12901)
2021 (14123)
2020 (12488)
2019 (10037)
2018 (7698)
2017 (7858)
2016 (7576)
2015 (8162)
2014 (5961)
2013 (4756)
2012 (4881)
2011 (5147)
2010 (4329)
Location
Africa (159)
Asia (7807)
Australia (1340)
California (759)
Canada (340)
China (38)
Colorado (45)
Connecticut (34)
Europe (21500)
Florida (76)
Georgia (29)
Illinois (66)
Indiana (35)
Maine (32)
Maryland (93)
Massachusetts (731)
Michigan (55)
Minnesota (46)
New Jersey (217)
New York (265)
North Carolina (152)
Northern California (371)
Ohio (49)
Pennsylvania (194)
South America (195)
Southern California (289)
Texas (121)
Utah (30)
Washington State (94)
141,943 Results for "elixirgen scientific".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioCapital
Elixirgen Scientific Achieves ISO 9001 QMS Certification
Baltimore-based biotechnology leader, Elixirgen Scientific, Inc., achieves ISO 9001:2015 Quality Management System certification, strengthening commitment to quality, excellence in biotechnology and drug discovery.
March 12, 2024
·
3 min read
Elixirgen Scientific, Inc. Achieves ISO 9001:2015 Certification, Strengthening Commitment to Quality, Excellence in Biotechnology
Elixirgen Scientific, Inc., a biotechnology leader focused on advancing drug discovery and revolutionizing cell therapy through iPSC technology, announced today that it has been accredited for ISO 9001:2015 certification.
March 8, 2024
·
3 min read
News
Elixirgen Scientific Launches Advanced hiPSC-Derived Disease Panel for Alzheimer’s Disease
July 16, 2024
·
2 min read
BioCapital
Elixirgen Therapeutics Presents Preclinical Data with Bobcat mRNATM Technology in Duchenne Muscular Dystrophy at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Elixirgen Therapeutics, Inc., today presented preclinical data on its proprietary Bobcat mRNA TM technology in a poster presentation at the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference taking place March 3-6, 2024, in Orlando, Florida.
March 4, 2024
·
2 min read
Press Releases
Elixirgen Therapeutics Receives Rare Pediatric Disease Designation for EXG-34217 in Dyskeratosis Congenita and Related Telomere Biology Disorders
September 26, 2024
·
2 min read
Drug Development
Elixirgen Therapeutics Announces Promising Phase 1/2 Data on EXG-5003, a Controllable Self-Replicating RNA (c-srRNA) Vaccine Against SARS-CoV-2
Elixirgen Therapeutics, Inc. today announced promising data from a Phase 1/2 trial (NCT04863131) evaluating EXG-5003, a SARS-CoV-2 vaccine developed with the Company’s temperature controllable self-replicating RNA (c-srRNA) technology.
October 16, 2023
·
4 min read
BioCapital
Elixirgen Therapeutics to Attend the 2023 Biotech Showcase Conference
Elixirgen Therapeutics, Inc. announced that members of the management team will be attending the Biotech Showcase Conference taking place January 9-11, 2023 in San Francisco, California.
January 4, 2023
·
1 min read
Business
Elixirgen Therapeutics Appoints Jeffrey L. Cleland, Ph.D., to Board of Directors
Elixirgen Therapeutics, Inc. today announced the appointment of Jeffrey L. Cleland, Ph.D., to the Board of Directors to support the advancement of its technology in developing therapies for a broad spectrum of diseases including rare diseases, aging-related disorders and cancer.
December 21, 2022
·
3 min read
BioCapital
Elixirgen Therapeutics Enters Memorandum of Understanding with Hitachi Global Life Solutions for the Development of Micro GMP Suites for Cell Therapy Administration
Elixirgen Therapeutics, Inc. today announced that it has entered a memorandum of understanding with Hitachi Global Life Solutions, Inc. (Hitachi GLS) for the development of Micro GMP suites to facilitate cell therapy administration.
January 26, 2023
·
2 min read
Drug Development
Elixirgen Therapeutics Presents New Clinical Data Demonstrating Ex Vivo Telomere Elongation with EXG-34217 in Dyskeratosis Congenita at the 64th ASH Annual Meeting
Elixirgen Therapeutics, Inc. today announced new data from a Phase 1/2 trial (NCT04211714) showing successful ex vivo telomere elongation with lead asset, EXG-34217 (autologous CD34+ hematopoietic stem cells that have been treated ex vivo with EXG-001), in a patient
December 12, 2022
·
4 min read
1 of 14,195
Next
